CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.
Authors
Alba Ariela Brandes
Alessandra Fabi
+13Â more
Alexandro Paccapelo
Alicia Tosoni
Claudia Caserta
Emanuela Proietti
Enrico Franceschi
Evaristo Maiello
Gaetano Finocchiaro
Giacomo Carteni
Giovanni Rosti
Matteo Clavarezza
Michele Reni
Raffaele Agati
Vittorina Zagonel
Publication date
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 25/10/2020